Table 1.
Baseline Characteristics of STEMI Patients From the RENASICA II Study (N = 4555)
| Variable | Value |
|---|---|
| Age, mean ± SD, y | 62 ± 12 |
| Male sex | 77 |
| Medical history, % | |
| Angina pectoris | 33 |
| DM | 43 |
| Smoking | 66 |
| Heart failure | 3 |
| Hypercholesterolemia | 26 |
| HTN | 50 |
| MI | 23 |
| PAD | 2 |
| Renal failure | 2 |
| Stroke | 2 |
| PTCA | 6 |
| CABG | 2 |
| Chest pain on admission, % | |
| Typical | 85 |
| Atypical | 9 |
| Systolic BP, mean ± SD, mm Hg | 125 ± 27 |
| High‐risk STEMI, %a | |
| Anterior | 56 |
| Inferior/posterior | 40 |
| Other | 4 |
| In‐hospital treatment, % | |
| ASA | 88 |
| ACE inhibitors | 64 |
| Angiotensin II inhibitors | 7 |
| Beta‐Blockers (oral) | 51 |
| CCB | 12 |
| Glycoprotein IIb/IIIa inhibitors | 16 |
| UFH | 54 |
| LMWH | 44 |
| Nitrates | 66 |
| Oral anticoagulation | 0.4 |
| Statins | 14 |
| Thienopyridines | 41 |
Abbreviations: ACE, angiotensin‐converting enzyme; ASA, aspirin; BP, blood pressure; CABG, coronary artery bypass grafting; CCB, calcium channel blockers; DM, diabetes mellitus; HTN, hypertension; LMWH, low‐molecular‐weight heparin; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; RENASICA II, Registro Nacional de Síndromes Coronarios Agudos II; SD, standard deviation; STEMI, ST‐elevation myocardial infarction; UFH, unfractionated heparin.
a
High‐risk STEMI was considered as a large ischemic area at risk for cardiogenic shock.